Studies of Apurinic/Apyrimidinic Endonuclease/ref-1 Expression in Epithelial Ovarian Cancer: Correlations with Tumor Progression and Platinum Resistance

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4689-4694

  Freitas, Sarah ^a   Moore, David H ^a   Michael, Helen ^a   Kelley, Mark R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; PLATINUM DERIVATIVE;

ARTICLE; CELL STRUCTURE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; EPITHELIUM TUMOR; EXCISION REPAIR; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; OVARY CANCER; OXIDATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REDUCTION; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; CELL NUCLEUS; DISEASE PROGRESSION; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 0142219356     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Chaney, S. G., and Sancar, A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. (Bethesda), 88: 1346-1360, 1996.
2. Masuda, H., Tanaka, T., Matsuda, H., and Kusaba, I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 50: 1863-1866, 1990.
3. Chou, K. M., and Cheng, Y. C. An exonucleolytic activity of human apurinic/apyrimidinic endonuclease on 3′ mispaired DNA. Nature (Lond.), 415: 655-659, 2002.
4. Hansen, W. K., and Kelley, M. R. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther., 295: 1-9, 2000.
5. Ramana, C. V., Boldogh, I., Izumi, T., and Mitra, S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc. Natl. Acad. Sci. USA, 95: 5061-5066, 1998.
6. Koukourakis, M. I., Giatromanolaki, A., Kakolyris, S., Sivridis, E., Georgoulias, V., Funtzilas, G., Hickson, I. D., Gatter, K. C., and Harris, A. L. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int. J. Radiat. Oncol. Biol. Phys., 50: 27-36, 2001.
7. Herring, C. J., West, C. M. L., Wilks, D. P., Davidson, S. E., Hunter, R. D., Berry, P., Forster, G., MacKinnon, J., Rafferty, J. A., Elder, R. H., Hendry, J. H., and Margison, G. P. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br. J. Cancer, 78: 1128-1133, 1998.
8. Moore, D. H., Michael, H., Tritt, R., Parsons, S. H., and Kelley, M. R. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin. Cancer Res., 6: 602-609, 2000.
9. Duguid, J. R., Eble, J. N., Wilson, T. M., and Kelley, M. R. Differential cellular and subcellular expression of the human multifunctional apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme. Cancer Res., 55: 6097-6102, 1995.
10. Xu, Y., Moore, D. H., Broshears, J., Liu, L., Wilson, T. M., and Kelley, M. R. The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res., 37: 13-20, 1997.
11. Xanthoudakis, S., Miao, G. G., and Curran, T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc. Natl. Acad. Sci. USA, 91: 23-27, 1994.
12. Yacoub, A., Kelley, M. R., and Deutsch, W. A. The DNA repair activity of human redox/repair protein APE/ref-1 is inactivated by phosphorylation. Cancer Res., 57: 5457-5459, 1997.
13. Shen, M. R., Jones, I. M., and Mohrenweiser, H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res., 58: 604-608, 1998.
14. Ford, B. N., Ruttan, C. C., Kyle, V. L., Brackley, M. E., and Glickman, B. W. Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis (Lond.), 21: 1977-1981, 2000.
15. Hu, J. J., Smith, T. R., Miller, M. S., Mohrenweiser, H. W., Golden, A., and Case, L. D. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis (Lond.), 22: 917-922, 2001.
16. Xanthoudakis, S., and Curran, T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J., 11: 653-655, 1992.
17. Xanthoudakis, S., Miao, G., Wang, F., Pan, Y. C., and Curran, T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J., 11: 3323-3325, 1992.
18. Mitomo, K., Nakayama, K., Fujimoto, K., Sun, X., Seki, S., and Yamamoto, K. Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-κB in vitro. Gene (Amst.), 145: 197-203, 1994.
19. Ema, M., Hirota, K., Mimura, J., Abe, H., Yodoi, J., Sogawa, K., Poellinger, L., and Fujii-Kuriyama, Y. Molecular mechanisms of transcriptional activation by HLF and HIF-1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J., 18: 1905-1914, 1999.
20. Jayaraman, L., Murthy, K. G., Zhu, C., Curran, T., Xanthoudakis, S., and Prives, C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev., 11: 558-570, 1997.
21. Lando, D., Pongratz, I., Poellinger, L., and Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1α and the HIF-like factor. J. Biol. Chem., 275: 4618-4627, 2000.
22. Prieto-Alamo, M. J., and Laval, F. Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugs. Carcinogenesis (Lond.), 20: 415-419, 1999.
23. Hirota, K., Matsui, M., Iwata, S., Mishiyama, A., Mori, K., and Yodoi, J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA, 94: 3633-3638, 1997.
24. Sasada, T., Iwata, S., Sato, N., Kitaoka, Y., Hirota, K., Nakamura, K., Nishiyama, A., Taniguchi, Y., Takabayashi, A., and Yodoi, J. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Investig., 97: 2268-2276, 1996.
25. Kakolyris, S., Kaklamanis, L., Engels, K., Fox, S. B., Taylor, M., Hickson, I. D., Gatter, K. C., and Harris, A. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. Br. J. Cancer, 77: 1169-1173, 1998.
26. Barret, J. M., and Hill, B. T. DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets. Anticancer Drugs, 9: 105-123, 1998.
27. Limp-Foster, M., and Kelley, M. R. DNA repair and gene therapy: implications for translational uses. Environ. Mol. Mutagen., 35: 71-81, 2000.